Social Media Sidebar


Please sign up, comment on articles and bring your friends!

Current poll

PlanetTech is asking:

What do you think about our new web site?

Love it, indeed
Really good solution
Same as old one
The old one was better
This is a new option

Quote of the day

Just because something doesn’t do what you planned it to do doesn’t mean it’s useless.


Thomas Edison

New Cancer Therapy Clinical Trial Leaves Three Patients Dead

Posted in Science on 11th Jul, 2016 06:15 PM by AlexMuller

Clinical trials of a promising new therapy, in which white blood cells are reprogrammed to attack cancer cells, has resulted in the deaths of three patients. In response, the US Food and Drug Administration has ordered a temporary halt to the trial. A promising new approach to cancer has a major setback. 

The new therapy, called JCAR015 (also known as the “ROCKET” trial), uses genetically engineered immune cells, known as CAR-T cells, to treat acute lymphoblastic leukemia (ALL) in adults, a cancer of the immune system that starts from the early version of white blood cells called lymphocytes in the bone marrow.
Once these juiced-up CAR-T cells are reintroduced into the patient’s bloodstream, they should prevent cancer from spreading and taking hold. In a study conducted earlier this year, 94 per cent of terminally ill patients who were treated with CAR-T went into remission.
Three patients, all under the age of 25, have died in a Juno Therapeutics Phase II clinical trial that’s been using the CAR-T cells to treat ALL. The patients died after excess fluids accumulated in their brains (cerebral edemas). In all cases, the deaths happened after a chemotherapy drug, fludarabine, was added to the treatment regimen.
The first death happened in May, but Juno wasn’t certain about the cause of death, saying “a change at that time was not warranted.” The subsequent deaths of two more patients, both from cerebral edemas, in the last week prompted the attention of the FDA, who issued an immediate, but temporary, halt to the trials.
Juno is blaming the deaths on the decision to introduce fludarabine into the treatment, a chemical cocktail that works to flush out the patient’s existing immune cells. Accordingly, the company has asked to re-start the trials, but without the benefit of fludarabine. The FDA wants Juno to revise its patient consent forms, investigative brochure, trial protocol, and a presentation it made to the FDA yesterday. Of the 90 patients expected to participate in the study, only 20 have been enrolled so far.
Despite Juno’s claim, there’s no conclusive evidence that the chemotherapy was responsible for the cerebral edemas. Dr. Stephan Grupp, a professor at the University of Pennsylvania Perelman School of Medicine, is in the midst of a similar trial that uses CAR-T cells to treat patients with paediatric acute lymphoblastic leukemia. He says it’s premature to pin the blame on fludarabine. Grupp’s team has not seen any significant brain swelling in their patients, who have been receiving the same chemotherapy drug. A few central nervous system issues have been observed, including confusion, aphasia, and seizures, but they’ve all all been resolved.
“Obviously, it is always hard to attribute toxicity to the chemo as opposed to the CAR-T cells when both are given around the same time, but we believe the self-limited CNS side effects we have reported from our study are more likely to be due to the T cells,” noted Grupp. “Right now, I don’t see this affecting other CAR-T trials or the field as a whole, since this issue appears not be seen more broadly. There may be some discussion about the appropriate role of the drug fludarabine, but this wouldn’t be a central issue.”

Tags: cancerclinical trialoncologyhealthmedicine

Read original article » Back to category


Author: Guest
Posted: 2016-07-12
These clinical trials used several agents and is now quite difficult to work out which of those caused severe and lethal side effects, more work is urgently needed Reply


Recent headlines

  • Posted in Software on 2018-05-26 01:48:47
    From Here to Human-Level AGI in Four Simple more
    Posted in Science on 2018-05-26 01:41:34
    Research Team Builds a Brain Model Neuron By more
    Posted in Hardware on 2018-05-24 04:45:19
    30% Efficiency Solar more
    Posted in Software on 2018-05-24 04:41:49
    Samsung plans AI research centers in Canada, UK more
    Posted in Science on 2018-05-24 04:38:06
    Every 3-5 years SpaceX is adding a decade lead more
Posted in Business on 2013-10-10 01:33
China is working towards a manned lunar mission in more
Posted in Business on 2013-10-20 07:17
Spacex says China is their main competitor for more
Posted in Software on 2013-10-20 06:43
Pirate Bay Browser Clocks 1,000,000 more
Posted in Medicine on 2013-10-10 02:10
Google reportedly investing hundreds of millions into more
Posted in Medicine on 2013-10-14 03:13
Endothelial Cells Can Repair and Regenerate Organs, more
Posted in Science on 01.01.2010
Spacex says China is their main competitor for more
Posted in Science on 01.01.2010
Staring at Your Phone Could Be Making You Short more
Posted in Science on 01.01.2010
Oculus Rift virtual reality headset coming to mobile, more
Posted in Science on 01.01.2010
China is working towards a manned lunar mission in more
Posted in Science on 01.01.2010
Delivering drugs via nanoparticles to target more

Recent Blog Posts

  • Posted by AlexMuller
    In five years quantum computing will be more
    Posted by AlexMuller
    Google partners with Johnson and Johnson to make lower more
    Posted by AlexMuller
    Electron holography microscope with spatial resolution down more
    Posted by AlexMuller
    Lower cost advanced Nuclear power could dominate future US more
    Posted by AlexMuller
    Why Hasn’t AI Mastered Language Translation? more

Login to your Account

Login to your PlanetTech Account here

Remember me

Create a New Account

You just need username and password

The following errors occured:
Verify password:
Remember me